メニューにジャンプ コンテンツにジャンプ
Disease Control and Prevention Center

Top > Publication list by year > Publications (2020)

Publications (2020)

Publication (International Journal)

  1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. PMID: 32445440; PMCID: PMC7262788.
  2. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med.2021 Mar 4;384(9):795-807.
  3. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Apr 10. doi:10.1056/NEJMoa2007016.
  4. Nangaku M, Kadowaki T, Yotsuyanagi H, Ohmagari N, Egi M, Sasaki J, Sakamoto T, Hasegawa Y, Ogura T, Chiba S, Node K, Suzuki R, Yamaguchi Y, Murashima A, Ikeda N, Morishita E, Yuzawa K, Moriuchi H, Hayakawa S, Nishi D, Irisawa A, Miyamoto T, Suzuki H, Sone H, Fujino Y. The Japanese Medical Science Federation COVID-19 Expert Opinion English Version. JMA J. 2021 Apr 15;4(2):148-162.
  5. Yamamoto K, Saito S, Hayakawa K, Hashimoto M, Takasaki J, Ohmagari N. When Clinicians Should Repeat RT-PCR for SARS-CoV-2: Repeat PCR Testing in Patients with Pulmonary CT Findings Suggestive of COVID-19. Jpn J Infect Dis. 74(2):161-165, 2021
  6. Yamamoto K, Mawatari M, Fujiya Y, Kutsuna S, Takeshita N, Hayakawa K, Nakamura M, Takanabe Y, Maruoka Y, Inoue M, Hara T, Nagasaka S, Tayama N, Miyazaki Y, Umeyama T, Ohmagari N. Survival case of rhinocerebral and pulmonary mucormycosis due to Cunninghamella bertholletiae during chemotherapy for acute myeloid leukemia: a case report. 49(1):165-170, 2021.
  7. Yamamoto K, Suzuki M, Yamada G, Sudo T, Nomoto H, Kinoshita N, Nakamura K, Tsujimoto Y, Kusaba Y, Morita C, Moriya A, Maeda K, Yagi S, Kimura M, Ohmagari N. Utility of the antigen test for coronavirus disease 2019: Factors influencing the prediction of the possibility of disease transmission. Int J Infect Dis. 104:65-72, 2021.
  8. Ujiie M. Trends in the incidence of reported adverse events after changing the Bacillus Calmette-Guérin vaccination age in Japan. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa1640.
  9. Ujiie M, Ohmagari N, Inoue H. Testing for COVID-19 at travel clinics in Japan. J Travel Med. 2020;27(5):taaa107.
  10. Ujiie M, Tsuzuki S, Ohmagari N. Effect of temperature on the infectivity of COVID-19. Int J Infect Dis. 2020;95:301-303.
  11. Takano T, Matsumura T, Adachi Y, Terahara K, Moriyama S, Onodera T, Nishiyama A, Kawana-Tachikawa A, Miki S, Hosoya-Nakayama K, Nakamura-Hoshi M, Seki S, Tachikawa N, Yoshimura Y, Miyata N, Horiuchi H, Sasaki H, Miyazaki K, Kinoshita N, Sudo T, Akiyama Y, Sato R, Suzuki T, Matano T, Takahashi Y. Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan. Int Immunol. 2021 Mar 31;33(4):241-247.
  12. Maeda K, Higashi-Kuwata N, Kinoshita N, Kutsuna S, Tsuchiya K, Hattori SI, Matsuda K, Takamatsu Y, Gatanaga H, Oka S, Sugiyama H, Ohmagari N, Mitsuya H. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.Sci Rep. 2021 Mar 10;11(1):5563.
  13. Sato L, Kinoshita N, Nakamoto T, Ohmagari N. Hemoptysis and a Newly Formed Lung Bulla in a Case of Convalescent COVID-19 Pneumonia.Intern Med. 2021 Mar 1;60(5):803-805.
  14. Saito S, Hayakawa K, Tsuzuki S, Ishikane M, Nagashima M, Mezaki K, Sugiki Y, Tajima T, Matsunaga N, Ide S, Kinoshita N, Kusama Y, Fujitomo Y, Nakamoto T, Toda Y, Kaku M, Kodama EN, Ohmagari N. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan. Antimicrob Agents Chemother.2021 Feb 17;65(3):e01483-20.
  15. Sugiyama M, Kinoshita N, Ide S, Nomoto H, Nakamoto T, Saito S, Ishikane M, Kutsuna S, Hayakawa K, Hashimoto M, Suzuki M, Izumi S, Hojo M, Tsuchiya K, Gatanaga H, Takasaki J, Usami M, Kano T, Yanai H, Nishida N, Kanto T, Sugiyama H, Ohmagari N, Mizokami M. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. 2021 Jan 15;766:145145.
  16. Suzuki T, Hayakawa K, Ainai A, Iwata-Yoshikawa N, Sano K, Nagata N, Suzuki T, Wakimoto Y, Akiyama Y, Miyazato Y, Nakamura K, Ide S, Nomoto H, Nakamoto T, Ota M, Moriyama Y, Sugiki Y, Saito S, Morioka S, Ishikane M, Kinoshita N, Kutsuna S, Ohmagari N. Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers. J Infect Chemother. 2021 Jan;27(1):120-122.
  17. Katagiri D, Ishikane M, Ogawa T, Kinoshita N, Katano H, Suzuki T, Fukaya T, Hinoshita F, Ohmagari N. Continuous Renal Replacement Therapy for a Patient with Severe COVID-19. Blood Purif. 2021;50(1):129-131.
  1. Osanai Y, Kinoshita N, Hayakawa K, Tanaka K, Hamano T, Kutsuna S, Ujiie M, Morioka S, Yamamoto K, Isikane M, Saito S, Sugiura Y, Ohmagari N.
    Telephone consults at the Infectious Disease Outpatient Clinic during the early period of the COVID-19 epidemic. Glob Health Med. 2020 Dec 31;2(6):392-394.
  2. Akiyama Y, Morioka S, Wakimoto Y, Kawashima A, Kanda K, Okuhama A, Suzuki T, Miyazato Y, Nomoto H, Ide S, Nakamoto T, Nakamura K, Ota M, Moriyama Y, Takaya S, Yamada K, Taguchi M, Sugito E, Izuka S, Ishiguro K, Kobayashi T, Miyake W, Kubota S, Ishikane M, Kinoshita N, Yamamoto K, Ujiie M, Kutsuna S, Hayakawa K, Saito S, Ohmagari N. Non-COVID-19 Patients with Life-threatening Diseases Who Visited a Fever Clinic: A Single-center, Observational Study in Tokyo, Japan. Intern Med. 2020 Dec 15;59(24):3131-3133.
  3. Nakamura K, Morioka S, Kutsuna S, Iida S, Suzuki T, Kinoshita N, Suzuki T, Sugiki Y, Okuhama A, Kanda K, Wakimoto Y, Ujiie M, Yamamoto K, Ishikane M, Moriyama Y, Ota M, Nakamoto T, Ide S, Nomoto H, Akiyama Y, Miyazato Y, Hayakawa K, Saito S, Ohmagari N. Environmental surface and air contamination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patient rooms by disease severity. Infect Prev Pract. 2020 Dec;2(4):100098.
  4. Nomoto H, Kutsuna S, Nakamura K, Nakamoto T, Shimomura A, Hirakawa T, Kinoshita N, Hayakawa K, Nagashima M, Ohmagari N. Totally implantable venous access port infection caused by Staphylococcus pseudintermedius: Possible transmission from a companion dog to a human.J Infect Chemother. 2020 Dec;26(12):1305-1308.
  5. Hayama H, Ishikane M, Sato R, Kanda K, Kinoshita N, Izumi S, Ohmagari N, Hiroi Y. NCGM COVID-19 clinical team. Association of plain computed tomography-determined pulmonary artery-to-aorta ratio with clinical severity of coronavirus disease 2019. Pulm Circ. 2020 Nov 20;10(4):2045894020969492.
  6. Okubo Y, Uda K, Kinoshita N, Horikoshi Y, Miyairi I, Michihata N, Matsui H, Fushimi K, Yasunaga H. National trends in appropriate antibiotics use among pediatric inpatients with uncomplicated lower respiratory tract infections in Japan. J Infect Chemother. 2020 Nov;26(11):1122-1128.
  7. Okuhama A, Ishikane M, Katagiri D, Kanda K, Nakamoto T, Kinoshita N, Nunose N, Fukaya T, Kondo I, Katano H, Suzuki T, Ohmagari N, Hinoshita F.
    Detection of SARS-CoV-2 in Hemodialysis Effluent of Patient with COVID-19 Pneumonia, Japan. Emerg Infect Dis. 2020 Nov;26(11):2758-2761.
  8. Katsuno T, Suzuki M, Ishikane M, Kinoshita N, Tsukada A, Morita C, Kusaba Y, Sakamoto K, Yamaguchi Y, Tsujimoto Y, Hashimoto M, Terada J, Takasaki J, Izumi S, Okuhama A, Ide S, Moriyama Y, Matsuda K, Takamatsu Y, Mitsuya H, Hojo M, Sugiyama H. A familial cluster of severe coronavirus disease 2019 that required intubation of all family members.Infect Dis (Lond). 2020 Oct;52(10):755-758.
  9. Okubo Y, Michihata N, Uda K, Kinoshita N, Horikoshi Y, Miyairi I. Impacts of Primary Care Physician System on Healthcare Utilization and Antibiotic Prescription: Difference-in-Differences and Causal Mediation Analyses. Pediatr Infect Dis J. 2020 Oct;39(10):937-942.
  10. Morioka S, Nakamura K, Iida S, Kutsuna S, Kinoshita N, Suzuki T, Suzuki T, Yamamoto K, Hayakawa K, Saito S, Ohmagari N. Possibility of transmission of severe acute respiratory syndrome coronavirus 2 in a tertiary care hospital setting: A case study.Infect Prev Pract. 2020 Sep;2(3):100079.
  11. Miyairi I, Shoji K, Kinoshita N, Saitoh J, Sugahara Y, Watanabe Y, Komura M, Kasai M, Horikoshi Y, Shinjoh M, Igarashi T. Prospective monitoring of carbapenem use and pseudomonal resistance across pediatric institutions. Pediatric Infection Control Network (PICoNet) for the Japanese Association of Children’s Hospitals and Related Institutions (JACHRI). Infect Control Hosp Epidemiol.2020 Sep;41(9):1042-1047
  12. Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori SI, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Transmission of SARS-CoV-2 in Domestic Cats. N Engl J Med. 2020 Aug 6;383(6):592-594.
  13. Katagiri D, Ishikane M, Asai Y, Kinoshita N, Ota M, Moriyama Y, Ide S, Nakamura K, Nakamoto T, Nomoto H, Akiyama Y, Miyazato Y, Suzuki T, Okuhama A, Kanda K, Wakimoto Y, Morioka S, Saito S, Yamamoto K, Ujiie M, Hayakawa K, Kustuna S, Yanagawa Y, Terada J, Takasaki J, Izumi S, Hojo M, Hinoshita F, Sugiyama M, Noiri E, Mizokami M, Ohmagari N, Sugiyama H. Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers. Crit Care Explor. 2020 Jul 31;2(8):e0170. doi: 10.1097/CCE.0000000000000170. eCollection 2020 Aug.PMID: 32766565 Free PMC article.
  14. Nomoto H, Ishikane M, Katagiri D, Kinoshita N, Nagashima M, Sadamasu K, Yoshimura K, Ohmagari N. Cautious handling of urine from moderate to severe COVID-19 patients. Am J Infect Control.2020 Aug;48(8):969-971.
  15. Suzuki T, Kutsuna S, Nakamura K, Ide S, Moriyama Y, Saito S, Morioka S, Ishikane M, Kinoshita N, Hayakawa K, Ohmagari N. Difficulty of downscaling the precautions for coronavirus disease-19 based on negative throat polymerase chain results in the early phase of infection. J Infect Chemother. 2020 Aug;26(8):851-853.
  16. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, Yasuhara A, Sakai-Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N, Ohmagari N, Hattori SI, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595.
  17. Kutsuna S, Suzuki T, Hayakawa K, Tsuzuki S, Asai Y, Suzuki T, Ide S, Nakamura K, Moriyama Y, Kinoshita N, Hosokawa N, Osawa R, Yamamuro R, Akiyama Y, Miyazato Y, Nomoto H, Nakamoto T, Ota M, Saito S, Ishikane M, Morioka S, Yamamoto K, Ujiie M, Terada M, Nakamura-Uchiyama F, Sahara T, Sano M, Imamura A, Sekiya N, Fukushima K, Kawana A, Fujikura Y, Sano T, Suematsu R, Sakamoto N, Nagata K, Kato T, Katano H, Wakita T, Sugiyama H, Kokudo N, Ohmagari N. SARS-CoV-2 Screening Test for Japanese Returnees From Wuhan, China, January 2020. Open Forum Infect Dis. 2020 Jun 20;7(7):ofaa243.
  18. Morioka S, Saito S, Hayakawa K, Takasaki J, Suzuki T, Ide S, Nakamura K, Moriyama Y, Akiyama Y, Miyazato Y, Nomoto H, Nakamoto T, Ota M, Sakamoto K, Katsuno T, Kusaba Y, Ishikane M, Kinoshita N, Yamamoto K, Ujiie M, Kutsuna S, Hashimoto M, Suzuki M, Izumi S, Katagiri D, Hojo M, Ohmagari N. Psychiatric burdens or stress during hospitalization and concerns after discharge in patients with severe acute respiratory syndrome coronavirus-2 isolated in a tertiary care hospital. Psychiatry Res. 2020 Jul;289:113040.
  19. Sato R, Ishikane M, Kinoshita N, Suzuki T, Nakamoto T, Hayakawa K, Bekki N, Hara H, Ohmagari N. A new challenge of unfractionated heparin anticoagulation treatment for moderate to severe COVID-19 in Japan.Glob Health Med. 2020 Jun 30;2(3):190-192. doi: 10.35772/ghm.2020.01044.PMID: 33330806 Free PMC article.
  20. Nakamura K, Ide S, Saito S, Kinoshita N, Kutsuna S, Moriyama Y, Suzuki T, Ota M, Nomoto H, Mizoue T, Hojo M, Takasaki J, Asai Y, Terada M, Akiyama Y, Miyazato Y, Nakamoto T, Wakimoto Y, Ujiie M, Yamamoto K, Ishikane M, Morioka S, Hayakawa K, Sugiyama H, Ohmagari N. COVID-19 can suddenly become severe: a case series from Tokyo, Japan. Glob Health Med. 2020 Jun 30;2(3):174-177
  1. Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. 2020 Jun 10;12(6):629.
  2. Kinoshita N, Komura M, Tsuzuki S, Shoji K, Miyairi I. The effect of preauthorization and prospective audit and feedback system on oral antimicrobial prescription for outpatients at a children's hospital in Japan. J Infect Chemother. 2020 Jun;26(6):582-587.
  3. Hayakawa K, Kutsuna S, Kawamata T, Sugiki Y, Nonaka C, Tanaka K, Shoji M, Nagai M, Tezuka S, Shinya K, Saito H, Harada T, Moriya N, Tsuboi M, Norizuki M, Sugiura Y, Osanai Y, Sugiyama M, Okuhama A, Kanda K, Wakimoto Y, Ujiie M, Morioka S, Yamamoto K, Kinoshita N, Ishikane M, Saito S, Moriyama Y, Ota M, Nakamura K, Nakamoto T, Ide S, Nomoto H, Akiyama Y, Suzuki T, Miyazato Y, Gu Y, Matsunaga N, Tsuzuki S, Fujitomo Y, Kusama Y, Shichino H, Kaneshige M, Yamanaka J, Saito M, Hojo M, Hashimoto M, Izumi S, Takasaki J, Suzuki M, Sakamoto K, Hiroi Y, Emoto S, Tokuhara M, Kobayashi T, Tomiyama K, Nakamura F, Ohmagari N, Sugiyama H. SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine. Glob Health Med. 2020 Apr 30;2(2):107-111.
  4. Kanamori K, Shoji K, Kinoshita N, Ishiguro A, Miyairi I. Complications of herpes zoster in children.Pediatr Int. 2019 Dec;61(12):1216-1220.
  5. Ide S, Hayakawa K, Yamamoto K, Tsuzuki S, Tanuma J, Ohara K, Yamada G, Okuhama A, Kanda K, Suzuki T, Akiyama Y, Miyazato Y, Nakamura K, Nomoto H, Nakamoto T, Ujiie M, Saito S, Morioka S, Ishikane M, Kinoshita N, Kutsuna S, Tanaka K, Ohmagari N. Positive ratio of polymerase chain reaction (PCR) and validity of pre-screening criteria at an outpatient screening center during the early phase of the COVID-19 epidemic in Japan. Jpn J Infect Dis. 2021 Feb 26. doi: 10.7883/yoken.JJID.2020.813. Epub ahead of print.
  6. Asai Y, Tsuzuki S, Kutsuna S, Hayakawa K, Ohmagari N. Effect of evacuation of Japanese residents from Wuhan, China, on preventing transmission of novel coronavirus infection: A modelling study. J Infect Chemother. 2021 Mar;27(3):515-520.
  7. Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, Terada M, Suzuki M, Kutsuna S, Saito S, Hayakawa K, Ohmagari N. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum Infect Dis. 2020 Oct 21;7(11):ofaa507.
  8. Saito S, Asai Y, Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Tsuzuki S, Ohmagari N. First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics. J Infect. 2021 Apr;82(4):84-123.
  9. Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, Suzuki S, Toyoda A, Suzuki K, Endo M, Fujii N, Suzuki M, Saito S, Uemura Y, Shibata T, Kondo M, Izumi K, Terada-Hirashima J, Mikami A, Sugiura W, Ohmagari N. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. Clin Infect Dis. 2020 Sep 28:ciaa1470. doi: 10.1093/cid/ciaa1470. Online ahead of print.
  10. Kutsuna S, Hayakawa K, Mezaki K, Yamamoto K, Ohmagari N. Spectrum of enteropathogens in cases of traveler's diarrhea that were detected using the FilmArray GI panel: New epidemiology in Japan. J Infect Chemother. 2021 Jan;27(1):49-54.
  11. Mills JP, Kaye KS, Evans R, Salzman E, Pogue J, Hayakawa K, Marchaim D, Awasthy P, Salim M, Martin ET. Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli Infections in Metro Detroit: Early Dominance of the ST-131 Clone. Infect Dis Ther. 2020 Sep;9(3):683-690.
  12. Kajihara T, Yahara K, Stelling J, Eremin SR, Tornimbene B, Thamlikitkul V, Hirabayashi A, Anzai E, Wakai S, Matsunaga N, Hayakawa K, Ohmagari N, Sugai M, Shibayama K. Comparison of de-duplication methods used by WHO Global Antimicrobial Resistance Surveillance System (GLASS) and Japan Nosocomial Infections Surveillance (JANIS) in the surveillance of antimicrobial resistance. PLoS One. 2020 Jun 26;15(6):e0228234.
  13. Muraki Y, Kusama Y, Tanabe M, Hayakawa K, Gu Y, Ishikane M, Yamasaki D, Yagi T, Ohmagari N. Impact of antimicrobial stewardship fee on prescribing for Japanese pediatric patients with upper respiratory infections. BMC Health Serv Res. 2020 May 11;20(1):399.
  14. Takaya S, Hayakawa K, Matsunaga N, Moriyama Y, Katanami Y, Tajima T, Tanaka C, Kimura Y, Saito S, Kusama Y, Morioka S, Fujitomo Y, Ohmagari N. Surveillance systems for healthcare-associated infection in high and upper-middle income countries: A scoping review. J Infect Chemother. 2020 May;26(5):429-437.
  15. Ishikane M, Kusama Y, Tanaka C, Hayakawa K, Kuwahara T, Ohmagari N. Epidemiology of Antimicrobial Use among Nursing Homes in Japan, 2016: a Pilot Study. Jpn J Infect Dis. 2020 Jul 22;73(4):293-295.
  16. Tsuzuki S, Matsunaga N, Yahara K, Gu Y, Hayakawa K, Hirabayashi A, Kajihara T, Sugai M, Shibayama K, Ohmagari N. National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. J Infect Chemother. 2020 Apr;26(4):367-371.
  17. Tajima T, Asai Y, Endo M, Suzuki T, Matsunaga N, Tsuzuki S, Hayakawa K, Ohmagari N. Rate of blood culture submissions in Japan as an indicator of bloodstream infections. J Infect Chemother.
  18. Shishido A, Otake S, Kimura M, Tsuzuki S, Fukuda A, Ishida A, Kasai M, Kusama Y. Effects of a nudge-based antimicrobial stewardship program in a pediatric primary emergency medical center. Eur J Pediatr. 2021 Feb 8.
  19. Tsuzuki Y, Hirata T*, Tsuzuki S, Wada S, Tamakoshi A. Risk Factors of Vaginal Cuff Infection in Women Undergoing Laparoscopic Hysterectomy for Benign Gynecological Diseases. Journal of Obstetrics and Gynecology Research. 2021 Feb 15 doi: 10.1111/jog.14632.
  20. Ujiie M*, Tsuzuki S, Suzuki M, Ota M, Suzuki T, Nomoto H, Yamamoto K, Saito S, Kokaze A, Kinoshita N. Safety of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine in adults in Japan. Jpn J Infect Dis. 2021 Jan 29. doi: 10.7883/yoken.JJID.2020.947.
  21. Morioka S*, Gu Y, Tsuzuki S, Fujitomo Y, Soeda H, Nakahama C, Hasegawa N, Maesaki S, Maeda M, Matsumoto T, Miyairi I, Ohmagari N. Determinants of clinic doctors’ attitudes concerning antimicrobial prescription for patients with common colds or bronchitis: additional analysis of a nationwide survey conducted by the Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. J Infect Chemother. 2021 Feb;27(2):131-138. doi: 10.1016/j.jiac.2020.11.017.
  22. Ono A, Ishikane M, Kusama Y*, Tanaka C, Ono S, Tsuzuki S, Muraki Y, Yamasaki D, Tanabe M, Ohmagari N. The First National Survey of Antimicrobial Use Among Dentists in Japan from 2015 to 2017 Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. PLoS One: PLoS One: 2020 Dec 28;15(12): e0244521. doi: 10.1371/journal.pone.0244521.
  23. Kusama Y*, Tsuzuki S, Muraki Y, Koizumi R, Ishikane M, Ohmagari N. The effects of Japan’s National Action Plan on Antimicrobial Resistance on antimicrobial use. Int J Infect Dis. 2020 Nov 20;103:154-156. doi: 10.1016/j.ijid.2020.11.158.
  24. Takaya S*, Tsuzuki S, Hayakawa K, Kawashima A, Okuhama A, Kanda K, Suzuki T, Akiyama Y, Miyazato Y, Ide S, Nakamura K, Nomoto H, Nakamoto T, Hikida S, Tanuma J, Ohara K, Ito T, Baba T, Yamamoto K, Ujiie M, Saito S, Morioka S, Ishikane M, Kinoshita N, Kutsuna S, Ohmagari N. Nightlife clusters of coronavirus disease in Tokyo between March and April 2020. Epidemiology and Infection. Oct 2020. DOI 10.1017/S0950268820002496.
  25. Tsuzuki S*, Akiyama T, Matsunaga N, Yahara K, Shibayama K, Sugai M, Ohmagari N. Improved penicillin susceptibility of Streptococcus pneumoniae and increased penicillin consumption in Japan, 2013–18. PLoS One. 2020 Oct 22;15(10):e0240655.
  26. Tsuzuki S*. Evaluation of non-pharmaceutical factors determine transmissibility of COVID-19: useful insights and future challenges. The Lancet Regional Health – Western Pacific. 2020 Sep DOI:https://doi.org/10.1016/j.lanwpc.2020.100030.
  27. Tsuzuki S*, Ishikane M, Matsunaga N, Morioka S, Yu J, Inagaki T, Yamamoto M, Ohmagari N. Interim 2019/2020 influenza vaccine effectiveness in Japan from October 2019 to January 2020. Jpn J Infect Dis. 2020 Sep 30. doi:10.7883/yoken.JJID.2020.177.
  28. Arima Y*, Kutsuna S, Shimada T, Suzuki M, Suzuki T, Kobayashi Y, Tsuchihashi Y, Nakamura H, Matsumoto K, Takeda A, Kadokura K, Sato T, Yahata Y, Nakajima N, Tobiume M, Takayama I, Kageyama T, Saito S, Nao N, Matsui T, Sunagawa T, Hasegawa H, Hayakawa K, Tsuzuki S, Asai Y, Suzuki T, Ide S, Nakamura K, Moriyama Y, Kinoshita N, Akiyama Y, Miyazato Y, Nomoto H, Nakamoto T, Ota M, Saito S, Ishikane M, Morioka S, Yamamoto K, Ujiie M, Terada M, Sugiyama H, Kokudo N, Ohmagari N, Ohnishi M, Wakita T, and the COVID-19 Response Team. Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Returnees to Japan from Wuhan, China, 2020. Emerg Infect Dis. 2020 Jul;26(7):1596-600.
  29. Tsuzuki S*, Matsunaga N, Ohmagari N. Road to comprehensive estimation of antimicrobial resistance (AMR) disease burden in Japan. Global Health and Medicine. 2020 May
  30. Miyazato Y, Ishikane M*, Inada M, Ohmagari N. Acute portal vein thrombosis with COVID-19 and cirrhosis. 2021;24:e01094. doi: 10.1016/j.idcr.2021.e01094. Epub 2021 Mar 27. PMID: 33816118; PMCID: PMC7999790.
  31. Morishita K, Takase K, Ishikane M, Otomo Y. Impact of incentives for health-care workers wearing personal protective equipment while dealing with coronavirus disease in Japan. J Occup Health. 2021 Jan;63(1):e12213. doi: 10.1002/1348-9585.12213. PMID: 33788328; PMCID: PMC8011358.
  32. Koizumi R, Kusama Y*, Muraki Y, Ishikane M, Yamasaki D, Tanabe M, Ohmagari N. Effect of population inflow and outflow between rural and urban areas on regional antimicrobial use surveillance. PLoS One. 2021 Mar 18;16(3):e0248338. doi: 10.1371/journal.pone.0248338. PMID: 33735299; PMCID: PMC7971456.
  33. Mita Y, Inose R, Goto R, Kusama Y, Koizumi R, Yamasaki D, Ishikane M, Tanabe M, Ohmagari N, Muraki Y*. An alternative index for evaluating AMU and anti-methicillin-resistant Staphylococcus aureus agent use: A study based on the National Database of Health Insurance Claims and Specific Health Checkups data of Japan. J Infect Chemother. 2021 Feb 19:S1341-321X(21)00040-4. doi: 10.1016/j.jiac.2021.02.009. Epub ahead of print. PMID: 33618976.
  34. Sakamoto H, Ishikane M, Ghaznavi C, Ueda P*. Assessment of Suicide in Japan During the COVID-19 Pandemic vs Previous Years. JAMA Netw Open. 2021 Feb 1;4(2):e2037378. doi: 10.1001/jamanetworkopen.2020.37378. PMID: 33528554; PMCID: PMC7856546.
  35. Katagiri D*, Ishikane M, Asai Y, Izumi S, Takasaki J, Katsuoka H, Kondo I, Ide S, Nakamura K, Nakamoto T, Nomoto H, Akiyama Y, Miyazato Y, Suzuki T, Kinoshita N, Ogawa T, Togano T, Suzuki M, Hashimoto M, Sakamoto K, Kusaba Y, Katsuno T, Fukaya T, Hojo M, Sugiyama M, Mizokami M, Okamoto T, Kimura A, Noiri E, Ohmagari N, Hinoshita F, Sugiyama H. Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. J Clin Apher. 2021 Jun;36(3):313-321. doi: 10.1002/jca.21861. Epub 2020 Dec 15. PMID: 33325084; PMCID: PMC8246724.
  36. Ishikane M, Mitsuhashi T, Motohashi A, Aozasa N*. Cutaneous Mycobacteroides chelonae Infection. Intern Med. 2021 Apr 1;60(7):1133-1134. doi: 10.2169/internalmedicine.4988-20. Epub 2020 Nov 9. PMID: 33162472; PMCID: PMC8079928.
  37. Nakamoto T, Ishikane M*, Sasaki R, Ohmagari N. Periungual desquamation in a Japanese Adult recovering from severe COVID-19. Int J Infect Dis. 2021 Jan;102:37-39. doi: 10.1016/j.ijid.2020.10.029. Epub 2020 Oct 17. PMID: 33075533; PMCID: PMC7567656.
  38. Kusama Y*, Ishikane M, Kihara T, Ohmagari N. Epidemiology of antibiotic treatment for uncomplicated cystitis in adults in Japan. J Infect Chemother. 2021 Jan;27(1):113-116. doi: 10.1016/j.jiac.2020.09.001. Epub 2020 Oct 1. PMID: 33011067.
  39. Suzuki T*, Kutsuna S, Nakamoto T, Ota M, Ishikane M, Yamamoto K, Maeki T, Tajima S, Nakayama E, Taniguchi S, Lim CK, Saijo M, Ohmagari N. Dengue Virus Serotype 1 Exported to Japan from Côte d'Ivoire, 2019. Jpn J Infect Dis. 2021 Mar 24;74(2):148-150. doi: 10.7883/yoken.JJID.2019.303. Epub 2020 Aug 1. PMID: 32741926.
  40. Minamimoto R*, Hotta M, Ishikane M, Inagaki T. FDG-PET/CT images of COVID-19: a comprehensive review. Glob Health Med. 2020 Aug 31;2(4):221-226. doi: 10.35772/ghm.2020.01056. PMID: 33330811; PMCID: PMC7731428.
  41. Goto R, Inose R, Kusama Y, Kawabe A, Ishii S, Ebisui A, Ishikane M, Yagi T, Ohmagari N, Muraki Y*. Trends of the Use of Anti-methicillin-Resistant Staphylococcus aureus Agents in Japan Based on Sales Data from 2006 to 2015. Biol Pharm Bull. 2020;43(12):1906-1910. doi: 10.1248/bpb.b20-00605. PMID: 33268708.
  42. Oda R, Inagaki T*, Ishikane M, Hotta M, Shimomura A, Sato M, Nakamoto T, Akiyama Y, Yamamoto K, Minamimoto R, Kaneko H, Ohmagari N. Case of adult large vessel vasculitis after SARS-CoV-2 infection. Ann Rheum Dis. 2020 Aug 11:annrheumdis-2020-218440. doi: 10.1136/annrheumdis-2020-218440. Epub ahead of print. PMID: 32788398.
  43. Kawabe A, Muraki Y*, Inose R, Kusama Y, Goto R, Ebisui A, Ishii S, Ishikane M, Ohge H, Ohmagari N. Trends of Antifungal Use Based on Sales Data in Japan from 2006 to 2015. Biol Pharm Bull. 2020;43(8):1248-1252. doi: 10.1248/bpb.b20-00302. PMID: 32741945.
  44. Taguchi M, Morioka S*, Ishikane M, Ohmagari N. Scrub Typhus with Respiratory Symptoms. Intern Med. 2020 Sep 15;59(18):2339-2340. doi: 10.2169/internalmedicine.4268-19. Epub 2020 Jun 15. PMID: 32536641; PMCID: PMC7578602.
  45. Ishikane M*, Miyazato Y, Kustuna S, Suzuki T, Ide S, Nakamura K, Morioka S, Katano H, Suzuki T, Ohmagari N. A Case of COVID-19 Patient with False-Negative for SARS-CoV-2 of Pharyngeal Swab, from a Chinese Traveller Returning from Wuhan, Hubei Province, China, January 2020. Jpn J Infect Dis. 2020 Nov 24;73(6):462-464. doi: 10.7883/yoken.JJID.2020.240. Epub 2020 May 29. PMID: 32475881.
  46. Nomoto H, Ishikane M*, Nakamoto T, Ohta M, Morioka S, Yamamoto K, Kutsuna S, Tezuka S, Kunimatsu J, Ohmagari N. Conjunctivitis, the key clinical characteristic of adult rubella in Japan during two large outbreaks, 2012-2013 and 2018-2019. PLoS One. 2020 Apr 24;15(4):e0231966. doi: 10.1371/journal.pone.0231966. PMID: 32330153; PMCID: PMC7182207.
  47. Sakamoto H, Ishikane M, Ueda P*. Seasonal Influenza Activity During the SARS-CoV-2 Outbreak in Japan. 2020 May 19;323(19):1969-1971. doi: 10.1001/jama.2020.6173. PMID: 32275293; PMCID: PMC7149351.
  48. Maeda M, Muraki Y*, Anno Y, Sawa A, Kusama Y, Ishikane M, Ohmagari N, Ohge H. Development of the predicted and standardized carbapenem usage metric: Analysis of the Japanese Diagnosis Procedure Combination payment system data. J Infect Chemother. 2020 Jun;26(6):633-635. doi: 10.1016/j.jiac.2020.02.006. Epub 2020 Mar 5. PMID: 32146108.
  49. Tsuzuki S*, Kimura Y, Ishikane M, Kusama Y, Ohmagari N. Cost of inappropriate antimicrobial use for upper respiratory infection in Japan. BMC Health Serv Res. 2020 Feb 28;20(1):153. doi: 10.1186/s12913-020-5021-1. PMID: 32111202; PMCID: PMC7048145.
  50. Kusama Y, Ishikane M*, Tanaka C, Kimura Y, Yamasaki D, Tanabe M, Muraki Y, Ohmagari N. Aminoglycoside inhalational therapy: a potential pitfall of antimicrobial stewardship in outpatient settings. JAC Antimicrob Resist. 2020 Feb 21;2(1):dlaa004. doi: 10.1093/jacamr/dlaa004. PMID: 34222962; PMCID: PMC8209994.
  51. Moriyama Y, Ishikane M*, Mezaki K, Ohmagari N. Comparison of penicillins (penicillin G and ampicillin) and cefazolin as a definitive therapy against penicillin-susceptible Staphylococcus aureus (PSSA) bacteremia in Japan: a retrospective cohort study. J Infect Chemother. 2020 Apr;26(4):358-362. doi: 10.1016/j.jiac.2019.10.023. Epub 2019 Dec 9. PMID: 31822451.
  52. Morioka S, Mori M, Suzuki T, Yokomichi M, Hamano J, Morita T. Determinants of physicians’ attitudes toward the management of infectious diseases in terminally-ill patients with cancer. Journal of Pain and Symptom Management. 60(6):1109-1116, 2020.
  53. Shrestha S, Tada T, Sherchan JB, Uchida H, Hishinuma T, Oshiro S, Morioka S, Kattel H, Kirikae T, Sherchand JB. Highly multidrug-resistant Morganella morganii clinical isolates from Nepal co-producing NDM-type metallo-β-lactamases and the 16S rRNA methylase ArmA. Journal of Medical Microbiology. 69(4):572-575, 2020.
  54. Sherchan JB, Tada T, Shrestha S, Uchida H, Hishinuma T, Morioka S, Shahi RK, Bhandari S, Twi RT, Kirikae T, Sherchand JB. Emergence of clinical isolates of highly carbapenem-resistant Klebsiella pneumoniae co-harboring blaNDM-5 and bla OXA-181 or -232 in Nepal. International Journal of Infectious Diseases. 92:247-252, 2020.
  55. Kutsuna S, Saito S , Ohmagari Simultaneous diagnosis of dengue virus, Chikungunya virus, and Zika virus infection using a new point-of-care testing (POCT) system based on the loop-mediated isothermal amplification (LAMP) method. J Infect Chemother. 2020 Dec;26(12):1249-1253.
  56. Nomoto H, et al. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity. J Infect Chemother. 2021 Apr;27(4):653-655. doi: 10.1016/j.jiac.2021.01.004.
  57. Kutsuna S, et al. Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19. J Infect Chemother. 2021 Jan 18:S1341-321X(21)00014-3. doi: 10.1016/j.jiac.2021.01.006.
  58. Yamayoshi S, et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. 2021 Feb;32:100734. doi: 10.1016/j.eclinm.2021.100734
  59. Ogyu A, Chan O, Littmann J, Pang HH, Lining X, Liu P, Matsunaga N, Ohmagari N, Fukuda K, and Wernli D. National Action to Combat Amr: A One-Health Approach to Assess Policy Priorities in Action Plans. BMJ Glob Health 5, no. 7 (Jul 2020).
  60. Tsuzuki S. and Yoshihara K. The Characteristics of Influenza-Like Illness Management in Japan. BMC Public Health 20, no. 1 (Apr 28 2020): 568.
  61. Jindai K, Kusama Y, Gu Y, Honda H, Ohmagari N. Narrative Review: The Process of Expanding the Manual of Antimicrobial Stewardship by the Government of Japan. Intern Med. 2021;60:181-90.
  62. Kusama Y, Ito K, Fukuda H, Matsunaga N, Ohmagari N. National database study of trends in bacteraemia aetiology among children and adults in Japan: a longitudinal observational study. BMJ Open. 2021 (in press)
  63. Gu Y. Raising awareness of antimicrobial resistance: comment on 'Reducing expectations for antibiotics in primary care: a randomised experiment to test the response to fear based messages about antimicrobial resistance'. BMC medicine. 2020;18(1):108.
  64. Yamagishi T, Ohnishi M, Matsunaga M, Kakimoto K, Kamiya H, Okamoto K, Suzuki M, Gu Y, Sakaguchi M, Tajima T, Takaya S, Ohmagari N, Takeda M, Matsuyama S, Shirato K, Nao N, Hasegawa H, Kageyama T, Takayama I, Saito S, Wada K, Fujita R, Saito H, Okinaka K, Griffith M, Parry AE, Barnetson B, Leonard J, Wakita T. Environmental Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 During a COVID-19 Outbreak on the Diamond Princess Cruise Ship. The Journal of infectious diseases. 2020;222(7):1098-1102.
  65. Shin JH, Mizuno S, Okuno T, Itoshima H, Sasaki N, Kunisawa S, Kaku M, Yoshida M, Gu Y, Morii D, Shibayama K, Ohmagari N, Imanaka Y. Nationwide multicenter questionnaire surveys on countermeasures against antimicrobial resistance and infections in hospitals. BMC Infect Dis. 2021;21(1):234.
  66. Tsuzuki S, Hayakawa K, Matsunaga N, Terada M, Suzuki S, Ohtsu H, Asai Y, Kitajima K, Saito S, Uemura Y, Shibata T, Kondo M, Izumi K, Hojo M, Mizoue T, Yokota K, Nakamura-Uchiyama F, Saito F, Sugiura W, Ohmagari N. Efficacy of remdesivir in Japanese patients hospitalised with COVID-19: A large observational study using the COVID-19 Registry Japan medRxiv (preprint) posted March 10 2021.
  67. Ujiie M, Tsuzuki S, Ohmagari N. Effect of temperature on the infectivity of COVID-19. Int J Infect Dis. 2020 Apr 30;95:301-303.

 Presentations at International Conferences and Forums

  1. Morioka S, Ohmagari N.
    What do we know about Long COVID from country experiences?
    The Long COVID Online Forum, 2020.
  2. Tsuzuki S.
    Deaths from bloodstream infections caused by antibiotic-resistant bacteria in Japan between 2015 and 2017: a population-level estimation.
    ECCMID2020, (2020.4) (Poster)
  3. Tajima T, Tsuzuki S, Asai Y, Endo M, Matsunaga N, Hayakawa K, Ohmagari N.
    Evaluation of Blood Culture Submission Rates in Japan.
    IDWeek 2020 (2020.10) (Poster)
  4. Endo M, Tsuzuki S, Asai Y, Tajima T, Matsunaga N, Hayakawa K, Ohmagari N.
    Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities.
    IDWeek 2020 (2020.10) (Poster)
  5. Tsuzuki S, Akiyama T, Matsunaga N, Yahara K, Shibayama K, Sugai M, et al.
    Improved Penicillin Susceptibility of Streptococcus pneumoniae and Increased Penicillin Consumption in Japan, 2013-18.
    IDWeek 2020 (2020.10) (Poster)

Publication list by year

Publications (2021)
Publications (2020)
Publications (2019)
Publications (2018)
Publications (2017)
Publications (2016)
Publications (2015)
Publications (2014)
Publications (2013)
Publications (2012)
Publications (2011)
Publications (2010)

Copyright (C) National Center for Global Health and Medicine,Disease Control and Prevention Center All rights reserved.